26-week Open Study of telmisartan40mg+amlodipine10mg or telmisartan80mg+amlodipine10 mg in Hypertension
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The primary objective of this trial is to assess the efficacy and safety of the fixed dose
combinations telmisartan 40mg/amlodipine 10mg (T40/A10) or telmisartan 80mg/amlodipine 10mg
(T80/A10) during open-label treatment for at least six months.
An additional objective is to assess the efficacy and safety of concomitant administration of
either T40/A10 or T80/A10 with any other therapies commonly used in the treatment of
hypertension.
The primary endpoint is the proportion of patients achieving DBP control (defined as mean
seated DBP < 90 mmHg at trough i.e. approximately 24 hours after last dose of study
treatment) at six months of treatment or at last trough observation during the treatment
period (i.e. last trough observation carried forward).